Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PLX Protalix BioTherapeutics

Pre-Mkt 01-12 05:40:29 EST

2.07

+0.07

+3.50%

High2.11	Low1.99	Vol1.58M
Open2.02	D1 Closing2.00	Amplitude5.75%
Mkt Cap166.47M	Tradable Cap125.76M	Total Shares80.42M
T/O3.24M	T/O Rate2.60%	Tradable Shares60.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PLX","market":"US","secType":"STK","nameCN":"Protalix BioTherapeutics","latestPrice":2.07,"timestamp":1767992400000,"preClose":2,"halted":0,"volume":1581150,"delay":0,"floatShares":60755281,"shares":80421181,"eps":0.069071,"marketStatus":"Pre-Mkt","change":0.07,"latestTime":"01-12 05:40:29 EST","open":2.02,"high":2.105,"low":1.99,"amount":3243540.43569,"amplitude":0.0575,"askPrice":2.25,"askSize":100,"bidPrice":1.9,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.069071,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768228200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":829022400000,"exchange":"AMEX","adjPreClose":2.07,"postHourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"18:54 EST","volume":13654,"amount":27955.12,"timestamp":1768002864291},"volumeRatio":1.2395141252397113,"impliedVol":0.6732,"impliedVolPercentile":0.416},"requestUrl":"/m/hq/s/PLX","defaultTab":"news","newsList":[{"id":"2601885135","title":"Protalix BioTherapeutics Projects Profitable Growth Anchored by Elfabrio Sales in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885135","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885135?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:50","pubTimestamp":1767613816,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics Inc. announced that it enters 2026 with a profitable commercial business through its partners and a focused pipeline targeting high unmet medical needs. The company expects future sales to continue being anchored by Elfabrio, marketed by partner Chiesi in the United States and key international markets. Protalix projects that Elfabrio is positioned to capture 15% to 20% of the global Fabry market, which is estimated to reach approximately $3.4 billion by 2030. The company remains committed to advancing its pipeline, including potential therapies for uncontrolled gout and rare renal diseases, while expanding its commercial footprint and pursuing strategic partnerships to accelerate growth and scale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL6NBN02:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2593904497","title":"Protalix BioTherapeutics CEO Dror Bashan Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593904497","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593904497?lang=en_us&edition=fundamental","pubTime":"2025-12-23 20:26","pubTimestamp":1766492792,"startTime":"0","endTime":"0","summary":"Dror Bashan, President and CEO of Protalix BioTherapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL3TypGn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Protalix BioTherapeutics CEO Dror Bashan Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2592994499","title":"Protalix BioTherapeutics and Secarna Pharmaceuticals partner to develop rare kidney disease therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994499","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994499?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:50","pubTimestamp":1765972217,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics Inc. has announced a collaboration and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to jointly develop novel antisense oligonucleotide  therapies for rare renal diseases. The partnership will combine Protalix's expertise in rare disease biologics with Secarna's AI-powered OligoCreator platform to discover and advance new pharmaceutical candidates. Under the agreement, Protalix is granted an exclusive option to license any active compounds resulting from the research for clinical development and commercialization, marking Protalix's first expansion into rare kidney disease therapies using RNA technologies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL3sZgZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2585117664","title":"Protalix BioTherapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117664","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585117664?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:31","pubTimestamp":1763724660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 06:31 ET (11:31 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX"],"gpt_icon":0},{"id":"2585422112","title":"Protalix price target lowered to $12 from $15 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2585422112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585422112?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:10","pubTimestamp":1763723430,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Protalix (PLX) to $12 from $15 and keeps a Buy rating on the shares f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protalix-price-target-lowered-to-12-from-15-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protalix-price-target-lowered-to-12-from-15-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2584922820","title":"Protalix BioTherapeutics Q3 EPS USD 0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2584922820","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584922820?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:37","pubTimestamp":1763573856,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Protalix BioTherapeutics Q3 pretax profit USD 2.239 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202511:00:00.18 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6SWMs1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2584925534","title":"Chiesi Global Rare Diseases Seeks Ema Chmp Re-Exam Of Negative View On Elfabrio 2 Mg/Kg Q4w Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925534?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:27","pubTimestamp":1763569669,"startTime":"0","endTime":"0","summary":"Nov 3 (Reuters) - CHIESI GLOBAL RARE DISEASES-:*CHIESI GLOBAL RARE DISEASES - REQUESTS RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY EMA'S CHMP ON PROPOSED DOSING REGIMEN OF 2 MG/KG EVERY 4 WEEKS FOR E","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1lLSpJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2584776999","title":"Bernstein Remains a Hold on PLUXEE N.V. (PLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584776999","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584776999?lang=en_us&edition=fundamental","pubTime":"2025-11-19 11:16","pubTimestamp":1763522162,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Sabrina Blanc from Bernstein maintained a Hold rating on PLUXEE N.V.. The company’s shares closed last Monday at €1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-pluxee-n-v-plx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-pluxee-n-v-plx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2584930939","title":"Kepler Capital  Remains a Buy on PLUXEE N.V. (PLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584930939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584930939?lang=en_us&edition=fundamental","pubTime":"2025-11-19 09:46","pubTimestamp":1763516767,"startTime":"0","endTime":"0","summary":"In a report released on November 17, Julien Richer from Kepler Capital maintained a Buy rating on PLUXEE N.V., with a price target of €28.00. The c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kepler-capital-remains-a-buy-on-pluxee-n-v-plx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kepler-capital-remains-a-buy-on-pluxee-n-v-plx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2584876479","title":"Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2584876479","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584876479?lang=en_us&edition=fundamental","pubTime":"2025-11-18 16:56","pubTimestamp":1763456200,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics Inc. has provided an update on its clinical and commercial pipeline. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from selling goods during the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash, with no debt or outstanding warrants, and anticipates becoming cash flow positive in the first half of 2027. The company's commercial portfolio includes approved enzyme replacement therapies for Fabry disease and Gaucher disease, with market presence in the US, EU, and additional regions. In its development pipeline, Protalix highlights PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, with Phase 2 studies expected to begin in the fourth quarter of 2025. The company also reports ongoing research in rare renal diseases and other NETs-related diseases. Key upcoming milestones include expanding market share for existing products, pursuing additional geographic approvals, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL8VvndK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2584840579","title":"Barclays Keeps Their Hold Rating on PLUXEE N.V. (PLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584840579","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584840579?lang=en_us&edition=fundamental","pubTime":"2025-11-18 16:16","pubTimestamp":1763453779,"startTime":"0","endTime":"0","summary":"Barclays analyst Pravin Gondhale maintained a Hold rating on PLUXEE N.V. today and set a price target of €20.00. According to TipRanks, Gondhale is...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-pluxee-n-v-plx-blurbs-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-pluxee-n-v-plx-blurbs-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLX"],"gpt_icon":0},{"id":"2583254938","title":"Protalix BioTherapeutics’ Earnings Call Highlights Growth and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2583254938","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583254938?lang=en_us&edition=fundamental","pubTime":"2025-11-14 08:37","pubTimestamp":1763080660,"startTime":"0","endTime":"0","summary":"Protalix Biotherapeutics (($PLX)) has held its Q3 earnings call. Read on for the main highlights of the call. Protalix BioTherapeutics’ recent earn...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/protalix-biotherapeutics-earnings-call-highlights-growth-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/protalix-biotherapeutics-earnings-call-highlights-growth-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLX"],"gpt_icon":0},{"id":"2583636562","title":"Protalix BioTherapeutics Q3 EPS USD 0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2583636562","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583636562?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:04","pubTimestamp":1763035494,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Protalix BioTherapeutics Q3 pretax profit USD 2.239 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202511:00:00.18 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nRSD6SWMs1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2583564535","title":"Protalix BioTherapeutics Q3 EPS $0.03 Misses $0.06 Estimate, Sales $17.673M Miss $17.866M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564535","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564535?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:51","pubTimestamp":1763034676,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.06 by 45.45 percent. This is unchanged from the same period last year.  The company","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48829545/protalix-biotherapeutics-q3-eps-0-03-misses-0-06-estimate-sales-17-673m-miss-17-866m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX"],"gpt_icon":0},{"id":"2583566564","title":"Press Release: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583566564","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583566564?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:50","pubTimestamp":1763034600,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:00 a.m. EST. CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.\"We are pleased to report total revenues of $43.6 million for the first nine months of 2025, an increase of 24%, compared to the same period in 2024. Our total revenues for the third quarter were $17.9 million which reflects a decrease of 1%, compared to revenues for the same period of 2024,\" said Dror Bashan, Protalix's President and Chief Executive Officer. \"We recognize revenues from sales of our products to Chiesi, Pfizer, and Fiocruz in Brazil, and their purchases vary from quarter to quarter as they control their ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU0170899867.USD","IE00B19Z3581.USD","SG9999002224.SGD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","EMA","SG9999001176.USD","BK4533","LU0306806265.USD","LU0225284248.USD","LU0225771236.USD","BK4139","BK4581","LU0122379950.USD","LU1066053197.SGD","LU0289739699.SGD","SG9999013999.USD","LU1883839398.USD","SG9999003800.SGD","BK4592","IE00BBT3K403.USD","PLX","SG9999002232.USD","BK4599","LU1066051498.USD","BK4534","LU0306807586.USD","LU0456855351.SGD","LU1894683264.USD","BK4081","SG9999011175.SGD","SG9999001176.SGD","LU1023059063.AUD","R","LU0868494617.USD","BK4568","IE0002270589.USD","LU0058720904.USD","BK4022","LU0321505439.SGD","LU0985481810.HKD","BK4007","CHMP","LU0321505868.SGD","BK4585","LU0234572021.USD","IE000M9KFDE8.USD","LU1894683348.USD"],"gpt_icon":1},{"id":"2581064332","title":"Protalix BioTherapeutics Inc. to Report Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581064332","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581064332?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:50","pubTimestamp":1762429816,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on November 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbd13VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2581511647","title":"Bernstein Reaffirms Their Hold Rating on PLUXEE N.V. (PLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581511647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581511647?lang=en_us&edition=fundamental","pubTime":"2025-11-05 00:35","pubTimestamp":1762274146,"startTime":"0","endTime":"0","summary":"Bernstein analyst Sabrina Blanc maintained a Hold rating on PLUXEE N.V. today and set a price target of €17.70. The company’s shares closed yesterd...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-hold-rating-on-pluxee-n-v-plx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-hold-rating-on-pluxee-n-v-plx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLX"],"gpt_icon":0},{"id":"2580278512","title":"Chiesi Global Rare Diseases Seeks Ema Chmp Re-Exam Of Negative View On Elfabrio 2 Mg/Kg Q4w Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580278512","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580278512?lang=en_us&edition=fundamental","pubTime":"2025-11-04 07:46","pubTimestamp":1762213595,"startTime":"0","endTime":"0","summary":"Nov 3 (Reuters) - CHIESI GLOBAL RARE DISEASES-:*CHIESI GLOBAL RARE DISEASES - REQUESTS RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY EMA'S CHMP ON PROPOSED DOSING REGIMEN OF 2 MG/KG EVERY 4 WEEKS FOR E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nRSD1lLSpJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2580263762","title":"Protalix BioTherapeutics and Chiesi Seek EMA Re-examination for Elfabrio Alternative Dosing in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2580263762","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580263762?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:44","pubTimestamp":1762206291,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics Inc. and Chiesi Global Rare Diseases have requested a re-examination from the European Medicines Agency  after receiving a negative opinion from the Committee for Medicinal Products for Human Use  regarding the proposed alternative dosing regimen of Elfabrio  at 2 mg/kg every four weeks. The currently approved dosing regimen of 1 mg/kg every two weeks remains in effect while the re-examination process is ongoing. The companies remain committed to working with the EMA to address the needs of the Fabry disease community.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL8ZTT7d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2580779429","title":"J.P. Morgan Sticks to Its Hold Rating for PLUXEE N.V. (PLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580779429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580779429?lang=en_us&edition=fundamental","pubTime":"2025-11-01 20:07","pubTimestamp":1761998822,"startTime":"0","endTime":"0","summary":"In a report released on October 30, Estelle Weingrod from J.P. Morgan maintained a Hold rating on PLUXEE N.V., with a price target of €23.00. The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-hold-rating-for-pluxee-n-v-plx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-hold-rating-for-pluxee-n-v-plx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protalix.com","stockEarnings":[{"period":"1week","weight":0.1897},{"period":"1month","weight":0.15},{"period":"3month","weight":-0.1229},{"period":"6month","weight":0.4681},{"period":"1year","weight":-0.0881},{"period":"ytd","weight":0.15}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.736842,"avgChangeRate":0.113685},{"month":2,"riseRate":0.388889,"avgChangeRate":0.044341},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.033546},{"month":4,"riseRate":0.578947,"avgChangeRate":0.056427},{"month":5,"riseRate":0.210526,"avgChangeRate":-0.051275},{"month":6,"riseRate":0.421053,"avgChangeRate":-0.034716},{"month":7,"riseRate":0.368421,"avgChangeRate":-0.04582},{"month":8,"riseRate":0.368421,"avgChangeRate":-0.012213},{"month":9,"riseRate":0.421053,"avgChangeRate":0.05112},{"month":10,"riseRate":0.421053,"avgChangeRate":-0.052252},{"month":11,"riseRate":0.368421,"avgChangeRate":-0.008211},{"month":12,"riseRate":0.421053,"avgChangeRate":-0.008649}],"exchange":"AMEX","name":"Protalix BioTherapeutics","nameEN":"Protalix BioTherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protalix BioTherapeutics(PLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protalix BioTherapeutics,PLX,Protalix BioTherapeutics股票,Protalix BioTherapeutics股票老虎,Protalix BioTherapeutics股票老虎国际,Protalix BioTherapeutics行情,Protalix BioTherapeutics股票行情,Protalix BioTherapeutics股价,Protalix BioTherapeutics股市,Protalix BioTherapeutics股票价格,Protalix BioTherapeutics股票交易,Protalix BioTherapeutics股票购买,Protalix BioTherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protalix BioTherapeutics(PLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction